Publicaciones en colaboración con investigadores/as de Eli Lilly and Company (35)

2024

  1. Design, synthesis and validation of a new Crimped Head-Piece for DNA-Encoded libraries generation

    Bioorganic and Medicinal Chemistry, Vol. 99

  2. High-Throughput DNA-Encoded Libraries Affinity Selection Platform for Binder Identification with Solid Support Protein Immobilization

    Assay and Drug Development Technologies, Vol. 22, Núm. 4, pp. 192-202

  3. Improved guidance is needed to optimise diagnostics and treatment of patients with thyroid cancer in Europe

    Endocrine, Vol. 83, Núm. 3, pp. 585-593

2023

  1. Epidemiological, Clinical, Patient-Reported and Economic Burden of Inflammatory Bowel Disease (Ulcerative colitis and Crohn’s disease) in Spain: A Systematic Review

    Advances in Therapy, Vol. 40, Núm. 5, pp. 1975-2014

  2. Genetic analysis of blood molecular phenotypes reveals common properties in the regulatory networks affecting complex traits

    Nature Communications, Vol. 14, Núm. 1

  3. Increased Medial Temporal Tau Positron Emission Tomography Uptake in the Absence of Amyloid-β Positivity

    JAMA neurology

  4. Persistence and Use of Ixekizumab in Patients with Psoriatic Arthritis in Real-World Practice in Spain. The PRO-STIP Study

    Rheumatology and Therapy, Vol. 10, Núm. 5, pp. 1319-1333

  5. Pharmacogenomics of GLP-1 receptor agonists: a genome-wide analysis of observational data and large randomised controlled trials

    The Lancet Diabetes and Endocrinology, Vol. 11, Núm. 1, pp. 33-41

2022

  1. Mapping genomic loci implicates genes and synaptic biology in schizophrenia

    Nature, Vol. 604, Núm. 7906, pp. 502-508

2021

  1. Normalization of DNA encoded library affinity selection results driven by high throughput sequencing and HPLC purification

    Bioorganic and Medicinal Chemistry, Vol. 40

2020

  1. A reference map of potential determinants for the human serum metabolome

    Nature, Vol. 588, Núm. 7836, pp. 135-140

  2. Complement genes contribute sex-biased vulnerability in diverse disorders

    Nature, Vol. 582, Núm. 7813, pp. 577-581

  3. Tanezumab for chronic low back pain: a randomized, double-blind, placebo- and active-controlled, phase 3 study of efficacy and safety

    Pain, Vol. 161, Núm. 9, pp. 2068-2078

2019

  1. Gene expression imputation across multiple brain regions provides insights into schizophrenia risk

    Nature Genetics, Vol. 51, Núm. 4, pp. 659-674

  2. Genetic studies of abdominal MRI data identify genes regulating hepcidin as major determinants of liver iron concentration

    Journal of Hepatology, Vol. 71, Núm. 3, pp. 594-602

  3. Publisher Correction: Common schizophrenia alleles are enriched in mutation-intolerant genes and in regions under strong background selection (Nature Genetics, (2018), 50, 3, (381-389), 10.1038/s41588-018-0059-2)

    Nature Genetics

  4. Publisher Correction: Gene expression imputation across multiple brain regions provides insights into schizophrenia risk (Nature Genetics, (2019), 51, 4, (659-674), 10.1038/s41588-019-0364-4)

    Nature Genetics

2018

  1. Age at first birth in women is genetically associated with increased risk of schizophrenia

    Scientific Reports, Vol. 8, Núm. 1

  2. Common schizophrenia alleles are enriched in mutation-intolerant genes and in regions under strong background selection

    Nature Genetics, Vol. 50, Núm. 3, pp. 381-389

  3. Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study

    The Lancet, Vol. 391, Núm. 10136, pp. 2213-2224